WO2024104663A1 - Procédé de réduction des mauvaises odeurs - Google Patents
Procédé de réduction des mauvaises odeurs Download PDFInfo
- Publication number
- WO2024104663A1 WO2024104663A1 PCT/EP2023/078131 EP2023078131W WO2024104663A1 WO 2024104663 A1 WO2024104663 A1 WO 2024104663A1 EP 2023078131 W EP2023078131 W EP 2023078131W WO 2024104663 A1 WO2024104663 A1 WO 2024104663A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- specified
- protein
- sirna
- apocrine
- reducing
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 111
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 claims abstract description 69
- 102100030350 Prolactin-inducible protein Human genes 0.000 claims abstract description 69
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 102000001045 Connexin 43 Human genes 0.000 claims abstract description 36
- 108010069241 Connexin 43 Proteins 0.000 claims abstract description 36
- 102100032361 Pannexin-1 Human genes 0.000 claims abstract description 28
- 101710165201 Pannexin-1 Proteins 0.000 claims abstract description 28
- 108010080192 Purinergic Receptors Proteins 0.000 claims abstract description 18
- 230000000699 topical effect Effects 0.000 claims abstract description 6
- 239000002773 nucleotide Substances 0.000 claims description 34
- 125000003729 nucleotide group Chemical group 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 33
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 102000008344 purinergic nucleotide receptor activity proteins Human genes 0.000 claims description 24
- 108020004999 messenger RNA Proteins 0.000 claims description 20
- 230000004853 protein function Effects 0.000 claims description 20
- 239000002781 deodorant agent Substances 0.000 claims description 12
- 102000010970 Connexin Human genes 0.000 claims description 7
- 108050001175 Connexin Proteins 0.000 claims description 7
- 108040002778 purinergic nucleotide receptor activity proteins Proteins 0.000 claims description 7
- 239000003205 fragrance Substances 0.000 claims description 5
- 208000035985 Body Odor Diseases 0.000 claims description 4
- 206010055000 Bromhidrosis Diseases 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 108060003345 Adrenergic Receptor Proteins 0.000 claims description 2
- 102000017910 Adrenergic receptor Human genes 0.000 claims description 2
- 102000000033 Purinergic Receptors Human genes 0.000 abstract 1
- 230000036773 apocrine secretion Effects 0.000 abstract 1
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 abstract 1
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 27
- 238000003197 gene knockdown Methods 0.000 description 18
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 17
- 230000004044 response Effects 0.000 description 12
- 210000000040 apocrine gland Anatomy 0.000 description 9
- 101100350972 Rattus norvegicus Panx1 gene Proteins 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 7
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000003248 secreting effect Effects 0.000 description 7
- 101100082449 Arabidopsis thaliana PBL21 gene Proteins 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 210000004243 sweat Anatomy 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000001166 anti-perspirative effect Effects 0.000 description 4
- 239000003213 antiperspirant Substances 0.000 description 4
- 229940095074 cyclic amp Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000000348 solid-phase epitaxy Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 3
- 229960002848 formoterol Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 2
- 102100037129 ATP-binding cassette sub-family C member 11 Human genes 0.000 description 2
- 108090000976 Aquaporin 5 Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001029057 Homo sapiens ATP-binding cassette sub-family C member 11 Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 210000000804 eccrine gland Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000002557 hidradenitis Diseases 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- TWQHGBJNKVFWIU-UHFFFAOYSA-N 8-[4-(4-quinolin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=C3C=CC=CC3=CC=2)C(=O)CC21CCCC2 TWQHGBJNKVFWIU-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 101150110927 ABCC11 gene Proteins 0.000 description 1
- 102000004392 Aquaporin 5 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 102100037601 P2X purinoceptor 4 Human genes 0.000 description 1
- QRLCJUNAKLMRGP-ZTWGYATJSA-N Penicillin F Chemical compound S1C(C)(C)[C@H](C(O)=O)N2C(=O)[C@@H](NC(=O)C/C=C/CC)[C@H]21 QRLCJUNAKLMRGP-ZTWGYATJSA-N 0.000 description 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241001620634 Roger Species 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- DNXNYEBMOSARMM-UHFFFAOYSA-N alumane;zirconium Chemical compound [AlH3].[Zr] DNXNYEBMOSARMM-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000002210 apocrine cell Anatomy 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Definitions
- the present invention relates to methods for reducing malodour on the surface of the human body and to cosmetic compositions enabling these methods.
- Typical antiperspirant actives are synthetic astringent salts based on aluminum and/or zirconium and these operate by blocking or partially blocking the sweat ducts on the surface of the human body and thereby reducing perspiration and malodour resulting therefrom.
- WO 02/011690 discloses an antiperspirancy method whereby calcium channels located in the secretory coil cells of the eccrine glands are blocked, thereby controlling sweat production at its source.
- siRNA oligonucleotides known as siRNA in antiperspirancy and odour reduction.
- siRNA are small interfering RNA molecules. Most of the siRNA are 20-30 nucleotides in length. siRNA molecules are involved in RNA interference and regulate (interfere with; silence) gene expression, post-transcriptionally. The 20-30 nucleotide length seems to maximize target gene specificity over non-specific effects.
- W02014/107124 discloses a treatment of hyperhidrosis involving the reduction of ITRP2 protein function and the use of specific siRNA molecules in such therapy.
- EP 3,270,881 B1 discloses the use of an siRNA for reducing perspiration by affecting specific calcium channel proteins in the eccrine glands of humans.
- WO2018/023126 discloses a method for treating osmidrosis comprising administration an inhibitor of an ABCC11 gene in a target cell, wherein the inhibitor may be an siRNA.
- WO2021/257630 discloses methods to reduce body odour and sweat volume using compositions that reduce ABCC11 transporter activity and/or AQP5 channel water conduction, the compositions including single-stranded RNA and DNA oligonucleotides that attenuate ABCC11 and AQP5 expression.
- an siRNA for use in treating bromhidrosis wherein the siRNA is capable of at least one of: reducing levels of specified protein mRNA; reducing levels of specified protein; reducing specified apocrine protein function; wherein the specified protein is selected from the P2-adrenoceptor, the P2Y R1 purinoceptor, and gap junction proteins connexin-43 and pannexin-1.
- the siRNA referred to in the above first aspect of the invention is capable of: (i) reducing levels of specified protein mRNA; (ii) reducing levels of specified protein; and/or (iii) reducing specified apocrine protein function.
- a non-therapeutic method of reducing malodour comprising the topical application of a composition comprising a cosmetically acceptable carrier and an siRNA that is capable of at least one of: reducing levels of specified apocrine protein mRNA; reducing levels of specified apocrine protein; reducing specified apocrine protein function; wherein the specified apocrine protein is selected from the P2-adrenoceptor, the P2Y R1 purinoceptor, and gap junction proteins connexin-43 and pannexin-1.
- the second aspect of the invention may alternatively be described as the non-therapeutic use of an siRNA for reducing malodour, wherein the siRNA is capable of at least one of: reducing levels of specified apocrine protein mRNA; reducing levels of specified apocrine protein; reducing specified apocrine protein function; wherein the specified apocrine protein is selected from the P2-adrenoceptor, the P2Y R1 purinoceptor, and gap junction proteins connexin-43 and pannexin-1.
- a deodorant composition comprising a cosmetically acceptable carrier and an siRNA that is capable of at least one of: reducing levels of specified protein mRNA; reducing levels of specified protein; reducing specified apocrine protein function; wherein the specified apocrine protein is selected from the P2-adrenoceptor, the P2Y R1 purinoceptor, and gap junction proteins connexin-43 and pannexin-1.
- deodorant compositions and methods include compositions and methods suitable for the reduction of malodour on the surface of the human body.
- an “apocrine protein” is a protein found within the secretory coil of human apocrine glands.
- compositions according to the invention are intended for topical application.
- topical application means application to the skin and does not mean application to the hair or internal cavities such as the mouth or nasal passages.
- Topical application to the underarm regions of the human body is particularly effective.
- application is directly onto the surface the human body.
- Deodorant compositions according to the invention comprise a cosmetically acceptable carrier but may take any physical form. Typical product formats include sprays, liquid rollons, gels, soft solids or sticks. Gels are a preferred product form.
- the inventors have discovered novel functionality for specific apocrine proteins in the apocrine glands of humans. Further, they have found that such proteins and their function can be affected by selected siRNA molecules, thereby reducing apocrine sweat secretion at its source.
- apocrine proteins identified as having relevance to human sweat production are the P2-adrenoceptor, the P2Y R1 purinoceptor, and gap junction proteins connexin-43 and pannexin-1.
- the present invention utilizes an siRNA selected in accordance with specified functional and/or chemical parameters, selected after extensive research in this area.
- the siRNA used in accordance with the present invention is capable of at least one of: reducing levels of specified apocrine protein mRNA; reducing levels of specified apocrine protein; reducing specified apocrine protein function; wherein the specified apocrine protein is selected from the P2-adrenoceptor, the P2Y R1 purinoceptor, and gap junction proteins connexin-43 and pannexin-1.
- apocrine proteins should be understood to be with respect to their presence in human sweat glands, in particular human apocrine glands.
- the present invention relates at least in part to the finding that one or more of the functional parameters listed above: reducing levels of the specified apocrine proteins mRNA; reducing levels of the specified apocrine proteins; reducing specified apocrine protein function; can lead to a reduction in malodour.
- the siRNA used in the present invention is thought to interfere with the mRNA of a specified apocrine protein and thereby reduce the level of said apocrine protein in cells to which the siRNA gains access.
- the specified apocrine proteins relevant to the present invention are involved in the regulation of cyclic adenosine monophosphate (cAMP) and calcium levels within human cells, in particular human apocrine cells. Some of the apocrine proteins are themselves receptors that mobilise cAMP and calcium levels within the apocrine secretory coil cells, whilst others promote cAMP and calcium movement between apocrine secretory coil cells (intercellular signalling).
- the P2Y R1 purinoceptor, and gap junction proteins connexin-43 and pannexin-1 are of particular relevance with regard to intracellular signalling.
- Cyclic AMP and calcium levels in the cells of human apocrine glands are critical to sweat generation.
- the present inventors have found a new method for manipulating intracellular cAMP and calcium levels in and between such cells and thereby reducing malodour.
- the siRNA used in accordance with the present invention is capable of at least one of: reducing levels of specified apocrine protein mRNA; reducing levels of specified apocrine protein; reducing specified apocrine protein function; wherein the specified apocrine protein is selected from the P2-adrenoceptor or the P2Y R1 purinoceptor.
- the siRNA used in accordance with the present invention is capable of at least one of: reducing levels of specified apocrine protein mRNA; reducing levels of specified apocrine protein; reducing specified apocrine protein function; wherein the specified apocrine protein is selected from the gap junction proteins connexin-43 and pannexin-1.
- the siRNA used in accordance with the present invention is capable of at least one of: reducing levels of specified apocrine protein mRNA; reducing levels of specified apocrine protein; reducing specified apocrine protein function; wherein the specified apocrine protein is selected from the P2Y R1 purinoreceptor, and gap junction proteins connexin-43 and pannexin-1.
- a combination of siRNAs may be employed, selected from the groups consisting of:
- siRNA capable reducing the level of the P2-adrenoceptor and an siRNA capable of reducing the level of gap junction protein connexin-43 or pannexin-1 (ii) An siRNA capable reducing the level of the P2Y R1 purinoreceptor and an siRNA capable of reducing the level of gap junction protein connexin-43 and/or pannexin-1.
- a combination of siRNAs may be employed, comprising:
- an siRNA capable of reducing the level of gap junction protein connexin-43 or pannexin-1 an siRNA capable of reducing the level of gap junction protein connexin-43 or pannexin-1 ; wherein a combination of siRNAs capable of reducing levels of specified protein mRNA; reducing levels of specified protein; and/or reducing specified apocrine protein function is employed; wherein the specified apocrine proteins include each of the P2Y R1 purinoreceptor and the gap junction protein connexin-43 and/or pannexin-1.
- a combination of siRNAs may be employed, the combination being capable of reducing levels of specified protein mRNA; reducing levels of specified protein; and/or reducing specified apocrine protein function; wherein the specified apocrine proteins include each of the P2Y R1 purinoreceptor and the gap junction protein connexin-43 and/or pannexin-1.
- siRNA sequences should be understood as being 5’ to 3’ sequences and that the code T denotes uracil.
- siRNA comprising a sequence selected from the group consisting of:
- a preferred siRNA of this type comprises SEQ ID 1.
- a particularly preferred siRNA of this type is of SEQ ID 1.
- siRNA comprising a sequence selected from the group consisting of:
- SEQ ID 2 TTGACTTTACTCAATCTTTGGTCTGTA and a portion comprising at least 25 nucleotides thereof, wherein the siRNA size is from 25 to 30 nucleotides.
- a preferred siRNA of this type comprises SEQ ID 2.
- a particularly preferred siRNA of this type is of SEQ ID 2.
- the siRNA used is as indicated in the paragraph immediately above.
- siRNA comprising a sequence selected from the group consisting of:
- SEQ ID 3 GAGTTTATACTGTATCTGCTTGTACCA and a portion comprising at least 25 nucleotides thereof, wherein the siRNA size is from 25 to 30 nucleotides.
- a preferred siRNA of this type comprises SEQ ID 3.
- a particularly preferred siRNA of this type is of SEQ ID 3.
- the siRNA used is as indicated in the paragraph immediately above.
- siRNA comprising a sequence selected from the group consisting of:
- SEQ ID 4 CAGTTTACTATCTCTCAGGTGCTTCCT and a portion comprising at least 25 nucleotides thereof, wherein the siRNA size is from 25 to 30 nucleotides.
- a preferred siRNA of this type comprises SEQ ID 4.
- a particularly preferred siRNA of this type is of SEQ ID 4.
- the siRNA used is as indicated in the paragraph immediately above.
- the siRNA used in the present invention comprises a sequence selected from the group consisting of:
- SEQ I D 1 AATACTTGAATAGTGAGGTAGATACAT;
- SEQ ID 2 TTGACTTTACTCAATCTTTGGTCTGTA;
- SEQ ID 3 GAGTTTATACTGTATCTGCTTGTACCA
- SEQ ID 4 CAGTTTACTATCTCTCAGGTGCTTCCT and a portion comprising at least 25 nucleotides of any of the above nucleotide sequences, wherein the siRNA size is from 25 to 30 nucleotides.
- the siRNA used in the present invention comprises a sequence selected from the group consisting of:
- SEQ ID 2 TTGACTTTACTCAATCTTTGGTCTGTA;
- SEQ ID 3 GAGTTTATACTGTATCTGCTTGTACCA
- SEQ ID 4 CAGTTTACTATCTCTCAGGTGCTTCCT and a portion comprising at least 25 nucleotides of any of the above nucleotide sequences, wherein the siRNA size is from 25 to 30 nucleotides.
- the siRNA size is typically from 25 to 30 nucleotides.
- the siRNA that works to provide the benefits of the invention may be as small as 25 nucleotides long and, in such cases, the desired nucleotide may be any portion of the sequences claimed in the present invention.
- the desired oligonucleotide may be as long as 30 nucleotides long and may comprise any one of the sequences in its entirety and, in addition, a few nucleotides attached at one or both ends.
- the siRNA is preferably present in a safe and effective amount in any composition of which it is a part.
- the siRNA is more preferably present in 0.00001 to 1%, more preferably 0.0001 to 0.01% by weight of the composition.
- compositions according to the invention comprise a cosmetically acceptable carrier.
- a cosmetically acceptable carrier is typically a fluid, the fluid comprising water in preferred embodiments, but being anhydrous in certain alternative embodiments of the invention.
- an anhydrous carrier comprises less than 1% of water and preferably less than 0.1%.
- carrier or ‘cosmetically acceptable carrier’ should be understood to include all components of the composition other than the siRNA or other deodorant active (excluding C1-C4 alcohols).
- the cosmetically acceptable carrier may include components such as emollients and/or humectants. Such components are typically used at from 0.1 to 10%.
- the cosmetically acceptable carrier may include oils, such as ester oils, ether oils, paraffin oils and silicone oils. Such components may be used at from 1 to 80%.
- a preferred component in compositions of the invention is a fragrance, typically at a level of from 0.1 to 5% of the total composition.
- the fragrance is preferably accompanied by a fragrance solubiliser, typically a non-ionic surfactant used a concentration of from 0.1 to 5% of the total composition.
- a further optional component is an organic anti-microbial agent.
- organic anti-microbial agent may be selected from any of those known in the art, provided reasonable skill is used to avoid any incompatibilities.
- An organic anti-microbial agent is a particularly preferred additional component when the composition used does not include a conventional, astringent aluminium containing antiperspirant salt. When employed, organic anti-microbial agents are typically used at a level of from 0.1 to 5% by weight of the composition.
- Thickening agents may be employed in compositions of the invention. Such agents increase the viscosity of or solidify the carrier fluid of the composition.
- Thickening agents may be selected from any of those known in the art, provided reasonable skill is used to avoid any incompatibilities.
- a preferred class of thickeners, especially for compositions also comprising water, are hydroxyalkyl celluloses, such as hydroxypropyl cellulose. When employed, thickening agents are typically used at a level of from 0.1 to 40%. When a hydroxyalkyl cellulose thickening agent is employed, this is typically used at a level of from 0.2 to 10% by weight.
- a preferred component of the carrier of compositions according to the invention is a skin penetration enhancer (SPE).
- SPE skin penetration enhancer
- Such materials are capable of aiding the transport of the siRNA from the skin surface to the apocrine and/or apocrine secretory coil cells. It is highly preferably that such materials are co-soluble with the siRNA employed.
- the SPE can be a solvent for the siRNA, the siRNA preferably having a solubility in the SPE of greater than 50 mmol. dm -3 , more preferably greater than 100 mmol. dm -3 .
- Suitable SPEs include oleic acid, azone, urea, transcutol, and ethanol.
- Preferred SPEs are short chain polyhydric alcohols, in particular C2 to C5 alcohols with 2-5 hydroxy groups, especially glycerol and propylene glycol.
- the SPE may be present at a level of 0.5-90% by weight of the composition in which it is employed, excluding any propellant that may be present. Preferably, this level is 1-50% by weight, more preferably from 2-30%, and most preferably from 3-12%.
- SPEs are SPACE peptides and SPACE-lipid carrier systems as disclosed in J. Controlled Release, 173, 2014, 67-74 and J. Controlled Release, 179, 2014, 33-41.
- SPEs are preferably part of an ethosomal carrier system and may preferably include 1,2-dioleoyl-3-trimethylammonium-propane (DOPAC) as a building block or be conjugated to a phospholipid.
- DOPAC 1,2-dioleoyl-3-trimethylammonium-propane
- compositions according to the invention comprise an astringent antiperspirant salt, such as aluminum and/or aluminum-zirconium salt.
- an astringent antiperspirant salt such as aluminum and/or aluminum-zirconium salt.
- such materials are typically present at from 1 to 50% of the composition of which they are part.
- compositions of the present invention can comprise a wide range of other optional components.
- CTFA Cosmetic Ingredient Handbook Second Edition, 1992, which is incorporated by reference herein in its entirety, describes a wide variety of non-limiting cosmetic and pharmaceutical ingredients commonly used in the skin care industry, which are suitable for use in the compositions of the present invention. Examples include: antioxidants, binders, biological additives, buffering agents, colorants, thickeners, polymers, astringents, fragrance, humectants, opacifying agents, conditioners, exfoliating agents, pH adjusters, preservatives, natural extracts, essential oils, skin sensates, skin soothing agents, and skin healing agents.
- composition of the invention is targeted for cosmetic and dermal applications and is therefore preferably not for therapeutic/ medical use, although such use is an alternative, non-excluded option.
- Apocrine sweat gland cellular responses were studied using an indefinitely proliferating human-derived apocrine secretory coil cell line (ASG5 cells; W02008/116713 A1 , Burry et al., 2008).
- ASG5 cells were grown in HuMEC basal serum free medium with added HuMEC supplement (containing epidermal growth factor, hydrocortisone, isoproterenol, transferrin and insulin, and 25mg of bovine pituitary extract) and 50 pg/ml penicillin I streptomycin (cHuMEC; Thermo Fisher Scientific, UK).
- Cells were cultured at 37°C in 5% CO2, split at 80-90% confluence, and subsequently washed twice with Dulbecco's phosphate-buffered saline (Thermofisher, UK). Cell detachment was achieved using the dissociating agent TrypLETM Select 1x (Life TechnologiesTM), which was inactivated by the addition of cHuMEC medium. Cell suspensions were used to seed fresh cultures in flask or plate formats.
- Short interfering RNAs (siRNA) against the P2-adrenoceptor and the ATP (adenosine triphosphate) purinoceptor P2Y R1 were purchased from Origene UK, and siRNA against connexin-43 (Cx43) and pannexin-1 (Px1) from Integrated DNA Technologies (IDT, UK).
- the P2-adrenoceptor siRNA had the sequence AATACTTGAATAGTGAGGTAGATACAT.
- the purinoceptor P2Y R1 siRNA had the sequence TTGACTTTACTCAATCTTTGGTCTGTA.
- the connexin-43 siRNA had the sequence GAGTTTATACTGTATCTGCTTGTACCA.
- pannexin-1 siRNA had the sequence CAGTTTACTATCTCTCAGGTGCTTCCT.
- Cells (at 70-80% confluency) were transfected with appropriately targeted siRNA at 10nM using a lipofectamine RNAiMax mix according to the manufacturer’s instructions.
- Transfected cells were washed twice with pre-warmed penicllin I streptomycin-free HuMEC and subsequently harvested for gene (24h post-transfection) and protein expression (48h post-transfection), or evaluated for cAMP and intracellular Ca 2+ ([Ca 2+ ]j) responses.
- cyclic AMP (cAMP) response of ASG5 cells was measured in the supernatant of treated cells by ELISA assay (ParameterTM ELISA, R&D Systems) following the manufacturer’s instructions and using a FLOUstar OPTIMA plate reader (Thermo Fisher Scientific, UK). Cyclic AMP responses were evoked by stimulation of the P2-adrenoceptor with the P2-selective agonist formoterol (Bio-techne, UK; ‘Control’ cells in Table 1) at 100 pM for 5min. Cyclic AMP concentration was calculated from a standard curve using MyAssay software.
- Intracellular Ca 2+ concentration ([Ca 2+ ]j) was measured in ASG5 cells seeded on to 25 mm 2 diameter glass coverslips (approx. 10 3 cells per coverslip).
- Cells were loaded the calcium-sensitive fluorescent indicator Fura-2 (Invitrogen, UK) by incubation (45 min - 1h, 37°C, in the dark) with the membrane-permeable acetoxymethyl ester form of the dye (Fura-2AM; 2.5 pM) in the presence of the non-ionic detergent Pluronic F127 (0.2% w/v; Sigma, UK).
- Fura-loaded cells were mounted in a specialised chamber attached to the stage of a Nikon T3000 inverted microscope (Nikon, UK) fitted with a Hamamatsu CCD camera (Hamamatsu Photonics, UK), and perfused (ca. 5ml/min, 37°C) with a physiological saline solution containing (mM): NaCI 134, KCI 6, MgCh 1, CaCI 2 1 , HEPES 10, D-glucose 10, pH 7.4 with NaOH.
- mM physiological saline solution containing
- cAMP and [Ca 2+ ]j are second messenger systems known to be effective in inducing fluid secretion in a wide variety of epithelial cell types.
- Our data show for the first time that apocrine sweat gland cells (ASG5 cells) produce a cAMP response following stimulation with the P2-adrenoceptor selective agonist formoterol, and a [Ca 2+ ]j response following stimulation with ATP.
- siRNA knockdown of the P2-adrenoceptor impairs the cAMP response, and knockdown of the P2Y R1 , Cx43 and Px1 inhibits the ATP-induced [Ca 2+ ]j response.
- siRNA knockdown of the P2-adrenoceptor impairs the cAMP response
- knockdown of the P2Y R1 , Cx43 and Px1 inhibits the ATP-induced [Ca 2+ ]j response.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne un procédé de réduction des mauvaises odeurs comprenant l'application topique d'une composition comprenant un ARNsi qui agit sur une protéine apocrine spécifiée pour réduire les sécrétions apocrines ; la protéine apocrine spécifiée étant choisie parmi le β2-adrénocepteur, le purinocepteur P2Y R1, et les protéines de jonction lacunaire telles que la connexine 43 et la pannexine 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22207666 | 2022-11-16 | ||
EP22207666.3 | 2022-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024104663A1 true WO2024104663A1 (fr) | 2024-05-23 |
Family
ID=84359232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/078131 WO2024104663A1 (fr) | 2022-11-16 | 2023-10-11 | Procédé de réduction des mauvaises odeurs |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024104663A1 (fr) |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002011690A1 (fr) | 2000-08-03 | 2002-02-14 | Unilever Plc | Produits antisudorifiques et deodorants et leurs procedes d'utilisation |
US7087743B2 (en) | 2000-02-11 | 2006-08-08 | Lvmh Recherche | Oligonucleotides and use of oligonucleotides modulating the expression of enzymes involved in the synthesis of melanic pigments, as depigmentation agents |
EP1752536A1 (fr) | 2004-05-11 | 2007-02-14 | RNAi Co., Ltd. | Polynucléotide provoquant l'interférence rna et procédé de regulation d'expression génétique avec l"usage de ce dernier |
US20070134188A1 (en) | 2005-09-21 | 2007-06-14 | L'oreal | Double-stranded RNA oligonucleotides which inhibit tyrosinase expression |
WO2008116713A2 (fr) | 2007-03-26 | 2008-10-02 | Unilever Plc | Lignée de cellules apocrines |
WO2009001359A2 (fr) | 2007-06-27 | 2008-12-31 | Quark Pharmaceuticals, Inc. | Compositions et procédés d'inhibition de l'expression de gènes pro-apoptotiques |
US7504385B2 (en) | 2003-12-17 | 2009-03-17 | Avon Products, Inc. | si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation |
US20090209627A1 (en) * | 2008-02-15 | 2009-08-20 | Alcon Research, Ltd. | RNAi-MEDIATED INHIBITION OF CONNEXIN 43 FOR TREATMENT OF IOP-RELATED CONDITIONS |
WO2010080452A2 (fr) | 2008-12-18 | 2010-07-15 | Quark Pharmaceuticals, Inc. | Composés d'arnsi et leurs procédés d'utilisation |
EP2213738A2 (fr) | 2002-11-14 | 2010-08-04 | Dharmacon, Inc. | Molécules siRNA anti Bcl-2 |
WO2013120726A2 (fr) | 2012-02-13 | 2013-08-22 | Unilever N.V. | Composition éclaircissant la peau |
WO2014107124A1 (fr) | 2013-01-03 | 2014-07-10 | Niklas Dahl | Traitement de l'hyperhidrose |
WO2018023126A1 (fr) | 2016-07-29 | 2018-02-01 | Kaspar Roger L | Procédés de traitement de l'osmidrose |
EP3270881B1 (fr) | 2015-03-20 | 2018-12-26 | Unilever PLC, a company registered in England and Wales under company no. 41424 of | Compositions antiperspirantes |
WO2021257630A2 (fr) | 2020-06-15 | 2021-12-23 | Cutler Richelle | Médicaments et procédés pour réduire l'odeur corporelle et la transpiration |
-
2023
- 2023-10-11 WO PCT/EP2023/078131 patent/WO2024104663A1/fr unknown
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087743B2 (en) | 2000-02-11 | 2006-08-08 | Lvmh Recherche | Oligonucleotides and use of oligonucleotides modulating the expression of enzymes involved in the synthesis of melanic pigments, as depigmentation agents |
WO2002011690A1 (fr) | 2000-08-03 | 2002-02-14 | Unilever Plc | Produits antisudorifiques et deodorants et leurs procedes d'utilisation |
EP2213738A2 (fr) | 2002-11-14 | 2010-08-04 | Dharmacon, Inc. | Molécules siRNA anti Bcl-2 |
US7504385B2 (en) | 2003-12-17 | 2009-03-17 | Avon Products, Inc. | si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation |
EP1752536A1 (fr) | 2004-05-11 | 2007-02-14 | RNAi Co., Ltd. | Polynucléotide provoquant l'interférence rna et procédé de regulation d'expression génétique avec l"usage de ce dernier |
US20070134188A1 (en) | 2005-09-21 | 2007-06-14 | L'oreal | Double-stranded RNA oligonucleotides which inhibit tyrosinase expression |
WO2008116713A2 (fr) | 2007-03-26 | 2008-10-02 | Unilever Plc | Lignée de cellules apocrines |
WO2009001359A2 (fr) | 2007-06-27 | 2008-12-31 | Quark Pharmaceuticals, Inc. | Compositions et procédés d'inhibition de l'expression de gènes pro-apoptotiques |
US20090209627A1 (en) * | 2008-02-15 | 2009-08-20 | Alcon Research, Ltd. | RNAi-MEDIATED INHIBITION OF CONNEXIN 43 FOR TREATMENT OF IOP-RELATED CONDITIONS |
WO2010080452A2 (fr) | 2008-12-18 | 2010-07-15 | Quark Pharmaceuticals, Inc. | Composés d'arnsi et leurs procédés d'utilisation |
WO2013120726A2 (fr) | 2012-02-13 | 2013-08-22 | Unilever N.V. | Composition éclaircissant la peau |
WO2014107124A1 (fr) | 2013-01-03 | 2014-07-10 | Niklas Dahl | Traitement de l'hyperhidrose |
EP3270881B1 (fr) | 2015-03-20 | 2018-12-26 | Unilever PLC, a company registered in England and Wales under company no. 41424 of | Compositions antiperspirantes |
WO2018023126A1 (fr) | 2016-07-29 | 2018-02-01 | Kaspar Roger L | Procédés de traitement de l'osmidrose |
WO2021257630A2 (fr) | 2020-06-15 | 2021-12-23 | Cutler Richelle | Médicaments et procédés pour réduire l'odeur corporelle et la transpiration |
Non-Patent Citations (24)
Title |
---|
"Posters", DIABETIC MEDICINE, JOHN WILEY & SONS, LTD, GB, vol. 22, 7 April 2005 (2005-04-07), pages 29 - 121, XP071684891, ISSN: 0742-3071, DOI: 10.1111/J.1464-5491.2005.01668.X * |
"The compositions of the present invention can comprise a wide range of other optional components", THE CTFA COSMETIC INGREDIENT HANDBOOK, 1992 |
ANONYMOUS: "ADRB2 siRNAs", 5 September 2023 (2023-09-05), pages 1 - 7, XP093078853, Retrieved from the Internet <URL:https://www.thermofisher.com/order/genome-database/SIRNA/gene/ADRB2#filters=primarygenes:^ADRB2$;;> [retrieved on 20230905] * |
ANONYMOUS: "beta2-AR siRNA (h): sc-39866", 17 November 2022 (2022-11-17), pages 1 - 1, XP093078901, Retrieved from the Internet <URL:https://datasheets.scbt.com/sc-39866.pdf> [retrieved on 20230905] * |
ANONYMOUS: "siRNA s1121", 5 September 2023 (2023-09-05), pages 1 - 2, XP093078886, Retrieved from the Internet <URL:https://www.thermofisher.com/order/genome-database/details/sirna/s1121> [retrieved on 20230905] * |
BABISOVÁ KLAUDIA ET AL: "Apocrine secretion in the salivary glands of Drosophilidae and other dipterans is evolutionarily conserved", vol. 10, 13 January 2023 (2023-01-13), CH, pages 1 - 25, XP093079189, ISSN: 2296-634X, Retrieved from the Internet <URL:http://dx.doi.org/10.3389/fcell.2022.1088055> DOI: 10.3389/fcell.2022.1088055 * |
HAYNES ET AL: "@b"2 and @b"3-adrenoceptor inhibition of @a"1-adrenoceptor-stimulated Ca^2^+ elevation in human cultured prostatic stromal cells", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 570, no. 1-3, 16 August 2007 (2007-08-16), pages 18 - 26, XP022202418, ISSN: 0014-2999, DOI: 10.1016/J.EJPHAR.2007.05.035 * |
J. CONTROLLED RELEASE, vol. 179, 2014, pages 33 - 41 |
LEE NAN SOOK ET AL: "Focused Ultrasound Stimulates ER Localized Mechanosensitive PANNEXIN-1 to Mediate Intracellular Calcium Release in Invasive Cancer Cells", FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, vol. 8, 23 June 2020 (2020-06-23), XP093079145, DOI: 10.3389/fcell.2020.00504 * |
LINDSAY S L ET AL: "Innervation and receptor profiles of the human apocrine (epitrichial) sweat gland: routes for intervention in bromhidrosis", BRITISH JOURNAL OF DERMATOLOGY, JOHN WILEY, HOBOKEN, USA, vol. 159, no. 3, 15 July 2008 (2008-07-15), pages 653 - 660, XP071128648, ISSN: 0007-0963, DOI: 10.1111/J.1365-2133.2008.08740.X * |
LOMA PATRICIA ET AL: "Beta2 adrenergic receptor silencing change intraocular pressure in New Zealand rabbits", vol. 11, no. 2, 1 April 2018 (2018-04-01), AMSTERDAM, NL, pages 69 - 74, XP093078891, ISSN: 1888-4296, Retrieved from the Internet <URL:https://pdf.sciencedirectassets.com/280299/1-s2.0-S1888429618X00028/1-s2.0-S1888429617300675/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEIX//////////wEaCXVzLWVhc3QtMSJHMEUCIHpk6S2NqtbQTJwYrvdVqLvF+/tc5fyJmHfPBPhWK8uMAiEAgWDqpy1rqPHmZL2SGBDS+mK5tqOH1yLvhca13FfqzScqswUIXRAFGgwwNTkwMDM1NDY4NjUiDE6e8> DOI: 10.1016/j.optom.2017.08.002 * |
MALMERSJÖ SETH ET AL: "Neural progenitors organize in small-world networks to promote cell proliferation", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 16, 1 April 2013 (2013-04-01), XP093079003, ISSN: 0027-8424, DOI: 10.1073/pnas.1220179110 * |
NADEALI ZAKIYE ET AL: "Possible role of pannexin 1 channels and purinergic receptors in the pathogenesis and mechanism of action of SARS-CoV-2 and therapeutic potential of targeting them in COVID-19", LIFE SCIENCE, PERGAMON PRESS, OXFORD, GB, vol. 297, 11 March 2022 (2022-03-11), XP087009763, ISSN: 0024-3205, [retrieved on 20220311], DOI: 10.1016/J.LFS.2022.120482 * |
ROGER TSEIN ET AL., J. BIOL. CHEM., vol. 260, 1985, pages 3440 - 3450 |
SILVIU LOCOVEI ET AL: "Pannexin1 is part of the pore forming unit of the P2X7 receptor death complex", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 581, no. 3, 16 January 2007 (2007-01-16), pages 483 - 488, XP071249607, ISSN: 0014-5793, DOI: 10.1016/J.FEBSLET.2006.12.056 * |
SNYDER E M ET AL: "Blood pressure variation in healthy humans: A possible interaction with @b-2 adrenergic receptor genotype and renal epithelial sodium channels", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 65, no. 2, 1 January 2005 (2005-01-01), pages 296 - 299, XP004909539, ISSN: 0306-9877, DOI: 10.1016/J.MEHY.2004.12.031 * |
STEFANIE GÖDECKE ET AL: "Thrombin-induced ATP release from human umbilical vein endothelial cells", AMERICAN JOURNAL OF PHYSIOLOGY CELL PHYSIOLOGY, vol. 302, no. 6, 15 March 2012 (2012-03-15), US, pages C915 - C923, XP055652954, ISSN: 0363-6143, DOI: 10.1152/ajpcell.00283.2010 * |
TAMARA MARTÍNEZ ET AL: "In Vitro and In Vivo Efficacy of SYL040012, a Novel siRNA Compound for Treatment of Glaucoma", MOLECULAR THERAPY, vol. 22, no. 1, 12 September 2013 (2013-09-12), pages 81 - 91, XP055189546, ISSN: 1525-0016, DOI: 10.1038/mt.2013.216 * |
TAMÁS DELI ET AL: "Contribution from P2X and P2Y purinoreceptors to ATP-evoked changes in intracellular calcium concentration on cultured myotubes", PFLÜGERS ARCHIV - EUROPEAN JOURNAL OF PHYSIOLOGY, SPRINGER, BERLIN, DE, vol. 453, no. 4, 17 October 2006 (2006-10-17), pages 519 - 529, XP019473999, ISSN: 1432-2013, DOI: 10.1007/S00424-006-0146-6 * |
WOLFE B B ET AL: "In Vitro Study of beta-Adrenergic Receptors", ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY., vol. 17, no. 1, 1 April 1977 (1977-04-01), US, pages 575 - 604, XP093079458, ISSN: 0362-1642, DOI: 10.1146/annurev.pa.17.040177.003043 * |
WYPYCH DOROTA ET AL: "P2Y1 nucleotide receptor silencing and its effect on glioma C6 calcium signaling.", vol. 59, no. 4, 31 December 2012 (2012-12-31), PL, XP093078925, ISSN: 0001-527X, Retrieved from the Internet <URL:https://ojs.ptbioch.edu.pl/index.php/abp/article/download/2115/751> DOI: 10.18388/abp.2012_2115 * |
YANG NAN ET AL: "Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells", vol. 22, no. 1, 1 December 2021 (2021-12-01), XP093078843, Retrieved from the Internet <URL:https://respiratory-research.biomedcentral.com/counter/pdf/10.1186/s12931-021-01659-2.pdf> DOI: 10.1186/s12931-021-01659-2 * |
YANG NAN ET AL: "Supplementary Information: Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells", RESPIRATORY RESEARCH, vol. 22, no. 1, 1 December 2021 (2021-12-01), pages S1 - S2, XP093078857 * |
YU YIQUN ET AL: "The role of connexin 43 in mediating odor response", vol. 94, no. 6, 1 June 2015 (2015-06-01), DE, pages 267 - 275, XP093079129, ISSN: 0171-9335, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S0171933515000369/pdfft?md5=66513c1b30a4e9ecf96d2c47e8afb78c&pid=1-s2.0-S0171933515000369-main.pdf> DOI: 10.1016/j.ejcb.2015.04.001 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10227594B2 (en) | Antiperspirant composition | |
EP3403673B1 (fr) | Composition pour empêcher ou améliorer la chute et le grisonnement des cheveux, et utilisation de cette dernière | |
JP2010150258A (ja) | 保湿効果又は老化防止効果を有する少なくとも2つの浸透圧調節物質を含有する化粧品組成物 | |
KR101938548B1 (ko) | 마이크로 rna를 포함하는 색소형성유전자 발현조절용 조성물 | |
KR20060123256A (ko) | 모발의 태모화 방법 및 조성물 | |
FR2790757B1 (fr) | Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant. | |
JP2019523302A (ja) | 腋臭を治療する方法 | |
KR101849102B1 (ko) | 마이크로 rna를 포함하는 색소형성유전자 발현조절용 조성물 | |
WO2024104663A1 (fr) | Procédé de réduction des mauvaises odeurs | |
WO2021257630A2 (fr) | Médicaments et procédés pour réduire l'odeur corporelle et la transpiration | |
ES2322583T3 (es) | Oligonucleotidos anti-androgenos utilizables en el tratamiento de trastornos dermatologicos relacionados con el metabolismo de los androgenos, sus composiciones farmaceuticas, sus usos y metodo de tratamiento. | |
KR20160016475A (ko) | Tslp 발현을 억제하는 올리고뉴클레오타이드 및 이를 포함하는 미용 또는 약제학적 조성물 | |
KR102541256B1 (ko) | Lipa 억제를 통한 흑색종 예방 또는 치료제, 및 그 스크리닝 방법 | |
EP4046635A9 (fr) | Composition comprenant un inhibiteur de la kinase rip, pour prévenir la chute des cheveux ou pour favoriser la repousse des cheveux | |
KR20170057194A (ko) | Tslp 발현을 억제하는 올리고뉴클레오타이드 및 이를 포함하는 미용 또는 약제학적 조성물 | |
US20220168206A1 (en) | Active agent for use in hair growth regulation | |
KR20180027157A (ko) | 아멘토플라본을 포함하는 피지 과다분비 또는 지루성 습진의 억제 또는 개선용 조성물 | |
KR101871920B1 (ko) | 마이크로 rna를 포함하는 조성물 | |
KR101800243B1 (ko) | 마이크로 rna를 포함하는 색소형성유전자 발현조절용 조성물 | |
EP3171879B1 (fr) | Prévention et traitement des maladies inflammatoires cutanées | |
KR102475128B1 (ko) | Entpd4 억제를 통한 흑색종 예방 또는 치료제, 및 그 스크리닝 방법 | |
KR20200041599A (ko) | Sh3bp4 억제를 통한 흑색종 예방 또는 치료제, 및 그 스크리닝 방법 | |
KR20210045916A (ko) | Rip 키나아제 억제제를 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
KR20200042231A (ko) | Linc00518 억제를 통한 베무라페닙 내성 흑색종 예방 또는 치료제, 및 그 스크리닝 방법 | |
KR101852440B1 (ko) | 듀옥스 2 miRNA를 포함하는 피부 세포 분화 조절용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23789896 Country of ref document: EP Kind code of ref document: A1 |